On April 1, 2026, the FDA approved Foundayo (orforglipron)—a once-daily oral GLP-1 receptor agonist from Eli Lilly. It is the first GLP-1 weight loss pill that can be taken at any time of day, with no restrictions on food or water intake. For millions of men who want the benefits of GLP-1 therapy but don't want to inject themselves weekly, this changes the equation.
What Makes Foundayo Different
Foundayo is a small-molecule, non-peptide GLP-1 receptor agonist. That's a technical distinction with practical implications. The existing oral GLP-1 option—Rybelsus (oral semaglutide)—is a peptide that must be taken on an empty stomach with no more than 4 oz of plain water, followed by a mandatory 30-minute fast. Many patients find this impractical and adherence suffers.
Foundayo eliminates all of that. Take it whenever. Eat whenever. No scheduling your morning around a pill.
How Well Does It Work?
The ATTAIN clinical program enrolled over 4,500 participants across two registration trials:
ATTAIN-1 (3,127 participants without diabetes): Dose-dependent weight loss of 7.5% to 11.2% at 72 weeks, compared to 2.1% with placebo. Participants also saw improvements in waist circumference, blood pressure, and lipid profiles.
ATTAIN-2 (1,613 participants with type 2 diabetes): Weight reductions of 5.1% to 9.6%, compared to 2.5% with placebo, plus significant improvements in HbA1c and cardiometabolic markers.
For context, injectable semaglutide (Wegovy) typically delivers 15–17% weight loss in trials. Foundayo's oral delivery comes at a trade-off in maximum efficacy—but for many men, the convenience of a daily pill versus a weekly injection is worth the difference.
Pricing and Access
| Access Path | Monthly Cost |
|---|---|
| Commercial insurance (with savings card) | As low as $25/month |
| Self-pay (LillyDirect) | Starting at $149/month |
| Medicare Part D (eligible) | $50/month (from July 1, 2026) |
Foundayo is available via LillyDirect with free home delivery and through US retail pharmacies. The $149/month self-pay price is for the lowest dose; maintenance doses at higher titration may cost more.
Side Effects and Safety
Foundayo carries the same class-level safety profile as other GLP-1 medications. The most common side effects are gastrointestinal: nausea, constipation, diarrhea, vomiting, and indigestion. Most are mild and tend to improve during dose titration.
What This Means for Men
Needle aversion is real—and it's a bigger barrier for men than most health providers acknowledge. Foundayo removes that barrier entirely. For men who've been aware of GLP-1 medications but haven't pursued them because of the injection factor, this is the option worth exploring.
That said, as of May 2026, Foundayo is brand-name only and not yet available through most compounding telehealth platforms. If you're considering compounded semaglutide or tirzepatide (which remain available through telehealth providers at lower price points), those are still strong options—especially while compounding pharmacies continue to operate under current regulations.
Compounded GLP-1 Options (Still Available)
Compounded medications are not FDA-approved. FDA does not evaluate compounded products for safety, effectiveness, or quality.
Compounded medications are not FDA-approved. FDA does not evaluate compounded products for safety, effectiveness, or quality.